pyrroles has been researched along with Weight Loss in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 10 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Coates, LC; Deal, C; Deodhar, A; Dubreuil, M; Dunham, J; Gladman, DD; Gottlieb, A; Guyatt, G; Husni, ME; Jonsson, AH; Kenny, S; Kwan-Morley, J; Lin, J; Magrey, M; Marchetta, P; Mease, PJ; Merola, JF; Miner, J; Nowell, WB; Ogdie, A; Orbai, AM; Reddy, SM; Reston, J; Ritchlin, CT; Scher, JU; Shah, AA; Siaton, B; Siegel, E; Siegel, M; Singh, JA; Smith, BJ; Sullivan, N; Turgunbaev, M; Turner, AS; Van Voorhees, AS; Walsh, JA | 1 |
| Abtahi Froushani, SM; Delirezh, N; Hobbenaghi, R; Mosayebi, G | 1 |
| Barter, PJ; DeMicco, DA; Messig, M; Ong, KL; Rye, KA; Waters, DD | 1 |
| Amniattalab, A; Hobbenaghi, R; Khoramjouy, M; Malekinejad, H | 1 |
| Bani, MR; Bassi, A; Bisighini, C; Damia, G; Fiordaliso, F; Ghilardi, C; Giavazzi, R; Moschetta, M; Piccirillo, R; Pretto, F; Rovida, A; Scarlato, V; Talamini, L | 1 |
| Azouz, MM; Bouassida, M; Chelbi, E; El Bouchtili, S; Ezzine, H; Hamzaoui, L; Mahmoudi, M; Medhioub, M; Touinsi, H | 1 |
| Chotiwat, C; Harris, RB | 1 |
| Audrain, O; Boucher, E; Leroux, C; Picot, D; Raoul, JL; Zoheir, Y | 1 |
| Balagué, C; Godessart, N; Pont, M; Prats, N | 1 |
| Eisen, T; Escudier, B; Izzedine, H; Mulders, P; Pyle, L; Robert, C; Sternberg, CN; Zbinden, S | 1 |
| Guan, F; Ju, J; Li, G; Liu, AB; Sun, Y; Yang, CS; Yang, Z | 1 |
| Benz, R; Suter, PM | 1 |
| Athyros, VG; Burroughs, AK; Didangelos, TP; Elisaf, MS; Giouleme, OI; Kakafika, AI; Karagiannis, A; Liberopoulos, EN; Mikhailidis, DP; Tziomalos, K | 1 |
| Nagy, A; Plonowski, A; Schally, AV | 1 |
2 review(s) available for pyrroles and Weight Loss
| Article | Year |
|---|---|
Targeted therapies for renal cell carcinoma: review of adverse event management strategies.
Topics: Anorexia; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cardiovascular System; Drug Eruptions; Europe; Everolimus; Evidence-Based Medicine; Gastrointestinal Tract; Humans; Hypothyroidism; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pneumonia; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Weight Loss; Wound Healing | 2012 |
[Low HDL-cholesterol, high triglycerides--well known but often ignored].
Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, HDL; Clofibric Acid; Combined Modality Therapy; Exercise; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Metabolic Syndrome; Niacin; Pyrroles; Risk Factors; Smoking Cessation; Triglycerides; Weight Loss; World Health Organization | 2004 |
2 trial(s) available for pyrroles and Weight Loss
| Article | Year |
|---|---|
Effect of change in body weight on incident diabetes mellitus in patients with stable coronary artery disease treated with atorvastatin (from the treating to new targets study).
Topics: Atorvastatin; Body Weight; Coronary Artery Disease; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Global Health; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Life Style; Male; Middle Aged; Pyrroles; Risk Factors; Time Factors; Weight Loss | 2014 |
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.
Topics: Anti-Obesity Agents; Atorvastatin; Diet, Fat-Restricted; Drug Therapy, Combination; Dyslipidemias; Fatty Liver; Female; Fenofibrate; Heptanoic Acids; Humans; Hypolipidemic Agents; Lactones; Male; Metabolic Syndrome; Middle Aged; Orlistat; Prevalence; Prospective Studies; Pyrroles; Risk Factors; Treatment Outcome; Ultrasonography; Weight Loss | 2006 |
11 other study(ies) available for pyrroles and Weight Loss
| Article | Year |
|---|---|
Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.
Topics: Abatacept; Adalimumab; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Psoriatic; Comorbidity; Diabetes Mellitus; Enthesopathy; Etanercept; Evidence-Based Medicine; Exercise; Glucocorticoids; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Infliximab; Interleukin-12; Interleukin-17; Interleukin-23; Occupational Therapy; Physical Therapy Modalities; Piperidines; Pyrimidines; Pyrroles; Rheumatology; Smoking Cessation; Societies, Medical; Spondylitis; Tumor Necrosis Factor-alpha; Ustekinumab; Weight Loss | 2019 |
Synergistic effects of atorvastatin and all-trans retinoic acid in ameliorating animal model of multiple sclerosis.
Topics: Animals; Atorvastatin; Brain; Cytokines; Disease Models, Animal; Drug Synergism; Encephalomyelitis, Autoimmune, Experimental; Female; Forkhead Transcription Factors; Heptanoic Acids; Mice; Multiple Sclerosis; Pyrroles; T-Lymphocytes, Regulatory; Tretinoin; Weight Loss | 2014 |
Atorvastatin attenuates the paraquat-induced pulmonary inflammation via PPARγ receptors: a new indication for atorvastatin.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Heptanoic Acids; Herbicides; Interleukin-6; Lung; Male; Malondialdehyde; Nitric Oxide; Paraquat; Peroxidase; Pioglitazone; Pneumonia; PPAR gamma; Pyrroles; Rats, Wistar; Thiazolidinediones; Tumor Necrosis Factor-alpha; Weight Loss | 2014 |
Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle.
Topics: Angiogenesis Inhibitors; Animals; Cachexia; Carcinoma, Renal Cell; Cell Line, Tumor; Female; Humans; Indoles; Kidney Neoplasms; Male; Mice, Inbred C57BL; Mice, Nude; Muscle Proteins; Muscle, Skeletal; Protein Kinase Inhibitors; Pyrroles; Signal Transduction; STAT3 Transcription Factor; Sunitinib; Time Factors; Tripartite Motif Proteins; Tumor Burden; Ubiquitin-Protein Ligases; Weight Loss; X-Ray Microtomography; Xenograft Model Antitumor Assays | 2015 |
Gastrointestinal stromal tumours (GISTs): A descriptive study on 29 cases.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Intestinal Neoplasms; Intestine, Small; Male; Middle Aged; Proto-Oncogene Proteins c-kit; Pyrroles; Retrospective Studies; Stomach Neoplasms; Sunitinib; Survival Rate; Tumor Burden; Weight Loss | 2016 |
Antagonism of specific corticotropin-releasing factor receptor subtypes selectively modifies weight loss in restrained rats.
Topics: Animals; Corticosterone; Corticotropin-Releasing Hormone; Dose-Response Relationship, Drug; Eating; Feeding Behavior; Infusions, Parenteral; Injections, Subcutaneous; Male; Peptide Fragments; Prosencephalon; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Corticotropin-Releasing Hormone; Restraint, Physical; Stress, Psychological; Time Factors; Weight Loss | 2008 |
I've heard that high-fat foods and alcohol can raise triglyceride levels. I take Lipitor for high cholesterol, don't eat high-fat foods and don't drink alcohol except for half a glass of wine a few times a month. My triglycerides are always high when chec
Topics: Anticholesteremic Agents; Atorvastatin; Exercise; Female; Heptanoic Acids; Humans; Male; Pyrroles; Triglycerides; Weight Loss | 2009 |
Changes in resting energy expenditure (REE) as a function of tumor response to sunitinib in a cachexic patient with a metastatic endocrine tumor of the pancreas.
Topics: Antineoplastic Agents; Cachexia; Calorimetry, Indirect; Eating; Energy Metabolism; Hepatectomy; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Pyrroles; Rest; Splenectomy; Sunitinib; Treatment Outcome; Weight Loss | 2010 |
Profiling of dihydroorotate dehydrogenase, p38 and JAK inhibitors in the rat adjuvant-induced arthritis model: a translational study.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Crotonates; Dihydroorotate Dehydrogenase; Dose-Response Relationship, Drug; Edema; Enzyme Inhibitors; Gastrointestinal Tract; Half-Life; Hydroxybutyrates; Hypercholesterolemia; Immunosuppressive Agents; Janus Kinases; Joints; Leukocyte Disorders; Male; Nitriles; Oxidoreductases Acting on CH-CH Group Donors; p38 Mitogen-Activated Protein Kinases; Piperidines; Pyrimidines; Pyrroles; Rats; Rats, Wistar; Splenomegaly; Toluidines; Weight Loss | 2012 |
Deleterious effects of high concentrations of (-)-epigallocatechin-3-gallate and atorvastatin in mice with colon inflammation.
Topics: Animals; Atorvastatin; Azoxymethane; Catechin; Colitis; Colon; Colonic Neoplasms; Dextran Sulfate; Dinoprostone; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Gastrointestinal Hemorrhage; Heptanoic Acids; Leukotriene B4; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Pyrroles; Rectum; Weight Loss | 2012 |
Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies.
Topics: Adult; Animals; Antineoplastic Agents; Bombesin; Carboxylesterase; Carboxylic Ester Hydrolases; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation, Preclinical; Drug Interactions; Drug Stability; Gonadotropin-Releasing Hormone; Half-Life; Humans; Hydrolysis; Isoflurophate; Male; Mice; Mice, Nude; Nitrophenols; Paraoxon; Pyrroles; Weight Loss | 2000 |